Evercore ISI Says Its Time To “Outperform” NovoCure (NVCR). Will Stock Hit Their Target of $46.0?

July 16, 2018 - By Margaret Guttierez

Why Has Evercore ISI Given NovoCure (NVCR) a $46.0 Price Target

Evercore ISI analyst has begun coverage on NovoCure (NVCR) with a $46.0 target and “Outperform” rating. The target gives a potential upside of 38.97 % from firm’s last stock price.

NovoCure Limited (NASDAQ:NVCR) Ratings Coverage

Among 2 analysts covering NovoCure (NVCR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NovoCure has $33 highest and $19 lowest target. $26’s average target is -27.58% below currents $35.9 stock price. NovoCure had 3 analyst reports since February 23, 2018 according to SRatingsIntel. Wedbush maintained the shares of NVCR in report on Friday, April 27 with “Outperform” rating. The firm earned “Hold” rating on Friday, February 23 by Deutsche Bank. On Thursday, April 19 the stock rating was upgraded by Deutsche Bank to “Buy”.

The stock increased 8.46% or $2.8 during the last trading session, reaching $35.9. About 1.37M shares traded or 48.62% up from the average. NovoCure Limited (NVCR) has risen 132.57% since July 16, 2017 and is uptrending. It has outperformed by 120.00% the S&P500.

Analysts await NovoCure Limited (NASDAQ:NVCR) to report earnings on July, 26. They expect $-0.15 EPS, up 37.50 % or $0.09 from last year’s $-0.24 per share. After $-0.23 actual EPS reported by NovoCure Limited for the previous quarter, Wall Street now forecasts -34.78 % EPS growth.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $3.26 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

More notable recent NovoCure Limited (NASDAQ:NVCR) news were published by: Benzinga.com which released: “31 Stocks Moving In Monday’s Mid-Day Session” on July 16, 2018, also Seekingalpha.com with their article: “Under Armour Is A Winner – Cramer’s Lightning Round (6/20/18)” published on June 21, 2018, Streetinsider.com published: “Evercore ISI Starts NovoCure Ltd. (NVCR) at Outperform” on July 16, 2018. More interesting news about NovoCure Limited (NASDAQ:NVCR) were released by: Investorplace.com and their article: “Trade of the Day: Novocure Ltd (NVCR)” published on July 06, 2018 as well as Nasdaq.com‘s news article titled: “Here’s Why Novocure Ltd. Rose 55% in the First Half of 2018” with publication date: July 14, 2018.

NovoCure Limited (NASDAQ:NVCR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.